Subject(s)
Aminophenols , Benzodioxoles , Cystic Fibrosis , Drug Combinations , Indoles , Pyrazoles , Quinolones , Humans , Benzodioxoles/therapeutic use , Cystic Fibrosis/drug therapy , Cystic Fibrosis/physiopathology , Aminophenols/therapeutic use , Indoles/therapeutic use , Quinolones/therapeutic use , Pyrazoles/therapeutic use , Male , Child , Adolescent , Female , Pyridines/therapeutic use , Pyrroles/therapeutic use , Quinolines/therapeutic use , Chloride Channel Agonists/therapeutic use , Chlorobenzenes/therapeutic use , Respiratory Function Tests , PyrrolidinesSubject(s)
Aminophenols , Benzodioxoles , Creatine Kinase , Cystic Fibrosis , Drug Combinations , Indoles , Pyrazoles , Rhabdomyolysis , Adolescent , Humans , Aminophenols/adverse effects , Aminophenols/therapeutic use , Benzodioxoles/adverse effects , Benzodioxoles/therapeutic use , Creatine Kinase/blood , Cystic Fibrosis/drug therapy , Cystic Fibrosis/complications , Indoles/adverse effects , Pyrazoles/adverse effects , Pyridines/adverse effects , Pyridines/therapeutic use , Pyrroles/adverse effects , Pyrrolidines , Quinolines/adverse effects , Quinolines/therapeutic use , Quinolones/adverse effects , Quinolones/therapeutic use , Rhabdomyolysis/chemically induced , Thiophenes/adverse effects , Thiophenes/therapeutic useABSTRACT
Rescue of N1303K CFTR by highly effective modulator therapy (HEMT) is enabled by CF airway inflammation. These findings suggest that evaluation of HEMT for rare CFTR mutations must be performed under inflammatory conditions relevant to CF airways. https://bit.ly/3tTcoJE.
ABSTRACT
BACKGROUND: Improvement in exocrine pancreatic function in persons with CF (pwCF) on cystic fibrosis transmembrane conductance regulator (CFTR) modulators has been documented in clinical trials using fecal pancreatic elastase-1 (FE-1). Our group endeavored to evaluate real-world data on FE-1 in children on CFTR modulator therapy at three pediatric cystic fibrosis (CF) centers. METHODS: Pediatric pwCF were offered FE-1 testing if they were on pancreatic enzyme replacement therapy (PERT) and on CFTR modulator therapy according to their center's guideline. FE-1 data were collected retrospectively. The primary outcome was absolute change in FE-1. RESULTS: 70 pwCF were included for analysis. 53 had baseline and post-modulator FE-1 values. There was a significant increase in FE-1 from median 25 mcg/g (IQR 25-60) at baseline to 57 mcg/g (IQR 20-228) post-modulator (p<0.001 by Wilcoxon matched pairs), with an absolute change in FE-1 of median 28 mcg/g (IQR -5-161) and mean 93.5 ± 146.8 mcg/g. Age was negatively correlated with change in FE-1 (Spearman r=-0.48, p<0.001). 15 pwCF (21%) had post-modulator FE-1 values ≥200 mcg/g, consistent with pancreatic sufficiency (PS). The PS group was significant for younger age at initiation of first CFTR modulator and a higher baseline FE-1. CONCLUSIONS: Most pwCF experienced an increase in FE-1 while receiving CFTR modulator treatment and a small percentage demonstrated values reflective of PS. These data suggest that PS may be attained in those that initiated modulator therapy at a younger age or had a higher baseline FE-1. FE-1 testing is suggested for children on any CFTR modulator therapy.
Subject(s)
Cystic Fibrosis , Child , Humans , Cystic Fibrosis/drug therapy , Cystic Fibrosis Transmembrane Conductance Regulator/metabolism , Mutation , Pancreas , Pancreatic Elastase/metabolism , Retrospective StudiesSubject(s)
Cystic Fibrosis , Humans , Cystic Fibrosis/complications , Cystic Fibrosis/drug therapy , Cystic Fibrosis/genetics , Pyridines , Cystic Fibrosis Transmembrane Conductance Regulator/genetics , Aminophenols/therapeutic use , Benzodioxoles/therapeutic use , Mutation , Chloride Channel Agonists/therapeutic use , Drug CombinationsABSTRACT
This pilot study successfully implemented a standardized protocol for tablet-based ototoxicity screening in pediatric cystic fibrosis (CF) patients exposed to aminoglycosides. Further studies are needed to assess the impact of implementation in a larger number of patients, as well as to determine barriers that may exist at centers with variation in available resources. This method of ototoxicity screening represents an accessible alternative to traditional audiology testing, and given the continued improvements in expected life span for people with CF, it is imperative that patients have regular access to this type of screening to allow for early identification of medication-related toxicities.
Subject(s)
Audiology , Cystic Fibrosis , Ototoxicity , Aminoglycosides/adverse effects , Anti-Bacterial Agents/adverse effects , Child , Cystic Fibrosis/drug therapy , Humans , Pharmacists , Pilot ProjectsABSTRACT
Pediatric pulmonary hypertension (PAH) is a rare disease that carries a poor prognosis if left untreated. Although there are published guidelines for the treatment of children with pulmonary hypertension, due to the limited number of robust pediatric clinical trials, recommendations are often based on limited data or clinical experience. Furthermore, many practical aspects of care, particularly for the pediatric patient, are learned through experience and best navigated with a multidisciplinary team. While newer PAH therapies have been approved for adults, there is still limited but expanding experience in pediatrics. This new information will help improve the targets of goal-oriented therapy. Lastly, this review highlights practical aspects in the use of the different therapies available for the treatment of pediatric pulmonary hypertension.
Subject(s)
Familial Primary Pulmonary Hypertension/drug therapy , Hypertension, Pulmonary/drug therapy , Pulmonary Arterial Hypertension/drug therapy , Adolescent , Adult , Bosentan/therapeutic use , Calcium Channel Blockers/therapeutic use , Child , Child, Preschool , Epoprostenol/administration & dosage , Epoprostenol/analogs & derivatives , Humans , Iloprost/administration & dosage , Infant , Infant, Newborn , Phenotype , Phenylpropionates/administration & dosage , Phosphodiesterase 5 Inhibitors/therapeutic use , Prognosis , Pyridazines/administration & dosage , Pyrimidines/administration & dosage , Receptors, Endothelin/metabolism , Sildenafil Citrate/therapeutic use , Sulfonamides/administration & dosage , Tadalafil/therapeutic use , Young AdultABSTRACT
Respiratory infections caused by non-tuberculous mycobacteria (NTM) are a major cause of morbidity for patients living with cystic fibrosis (CF), as NTM pulmonary disease (NTM-PD) is challenging to both diagnose and eradicate. Despite the lengthy courses of the established regimens recommended by the Cystic Fibrosis Foundation (CFF) and European Cystic Fibrosis Society (ECFS) consensus guidelines, only about 50% to 60% of patients achieve culture conversion, and treatment regimens are often complicated by antibiotic resistance and toxicities. Since publication of the CFF/ECFS guidelines, several new or alternative antibiotic regimens have been described for patients with CF who have NTM-PD. These regimens offer new options for patients who do not clear NTM with standard therapies or cannot utilize the usual regimens due to toxicities or drug-drug interactions.